Metagenomi Therapeutics, Inc. income statement

In fiscal 2025, Metagenomi Therapeutics, Inc. reported revenue of $25.2m, down 51.8% on the year before, operating income of −$96.0m (a -380.9% margin) and net income of −$87.9m, or −$2.36 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Metagenomi Therapeutics, Inc.: income statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMMar 2026
Revenue	45	52	25	22
Research and development	94	109	94	89
General and administrative	29	32	27	27
Operating income	−78	−89	−96	−93
Income before tax	−60	−84	−88	−86
Income tax	8	−6	−0	−0
Net income	−68	−78	−88	−86
Diluted EPS	−$2.00	−$2.36	−$2.36	−$2.30
Diluted shares (average)	34m	33m	37m	37m
EBITDA	−74	−83	−91	−88

US$ millions unless shown otherwise. Fiscal quarters.

Metagenomi Therapeutics, Inc.: income statement, quarterly
Quarter	2024 Q2Jun 2024	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026
Revenue	20	12	10	4	9	9	4	1
Research and development	28	26	23	25	23	25	22	19
General and administrative	9	8	7	7	7	6	7	7
Operating income	−17	−22	−21	−28	−21	−23	−24	−25
Income before tax	−13	−21	−25	−25	−20	−21	−22	−23
Income tax	−2	−2	−1	0	0	−0	0	0
Net income	−11	−19	−23	−25	−20	−20	−23	−23
Diluted EPS	−$0.29	−$0.51	−$0.63	−$0.68	−$0.54	−$0.55	−$0.60	−$0.61
EBITDA	−16	−21	−19	−26	−20	−22	−23	−23

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: JANX vs MGX CRSP vs MGX ABEO vs MGX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Metagenomi Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Metagenomi Therapeutics, Inc.